Not Yet RecruitingEarly Phase 1

Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL)

600 participantsStarted 2021-06-30

Plain-language summary

Study is testing the efficacy of treating corneal thinning conditions with Vitamin B2 (Riboflavin) and the application on UV Light.

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, acanthamoeba, etc.)
✕. Clinically significant corneal scarring in the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross linking procedure

Change in Best Corrected Visual Acuity

Timeframe: Baseline and 1 year

Change in Uncorrected Visual Acuity

Timeframe: Baseline and 1 year

Occurrence of Adverse Events

Timeframe: Through study completion, an average of 1 year

NCT IDNCT04731727

SponsorKent Wellish MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Tony F Sterrett